Synthesis of novel nilotinib analogues and biological evaluation of their antiplatelet activity and functionality towards cancer cell proliferation in vitro
L Pechlivani, N Ntemou, D Pantazi, D Alivertis… - Pharmaceuticals, 2024 - mdpi.com
Nilotinib, a second-generation tyrosine kinase inhibitor for the treatment of chronic
myelogenous leukemia (CML), inhibits Bcr-Abl tyrosine kinase activity and proliferation of …
myelogenous leukemia (CML), inhibits Bcr-Abl tyrosine kinase activity and proliferation of …